Australia’s TGA already considers non-animal evidence in therapeutic-goods assessment. Its October 2026 statement ties acceptance of a NAM to its intended use, human biological relevance, technical performance and reliability, with validation evidence scaled to the consequences of a wrong conclusion.
The Therapeutic Goods Administration (TGA) says it already considers non-animal data when assessing the safety, quality and efficacy of therapeutic goods in Australia. A sponsor proposing to rely on a novel NAM for a clinical trial or marketing application is encouraged to contact the regulator early. The October 2026 statement describes the agency’s approach to these submissions rather than announcing a new blanket replacement for animal studies.
TGA assesses NAMs evidence alongside other information under a weight-of-evidence approach. A method designed to answer one biological question may not capture whole-body effects or interactions among organs. The agency therefore considers each proposed use and its remaining uncertainty, rather than treating the existence of a NAM as sufficient grounds for one-for-one substitution.
The statement also places NAMs within existing regulatory practice. TGA already uses computational genotoxicity assessment and safety read-across for impurities in premarket and postmarket work. Internationally recognized scientific guidelines adopted by TGA help set expectations for nonclinical development.
The first consideration is context of use: what question the method addresses and which development or regulatory decision its data would inform. The second is human biological relevance, including the relationship between the measured endpoint and the human event or outcome of interest. Sponsors should state whether the method supplements existing data or is intended to replace a particular study.
Technical characterization covers how the test is run, its endpoints and controls, sources of variability, and evidence that it produces credible results. Fitness for purpose then asks whether the method is sufficiently robust and reliable for the particular decision. TGA also asks sponsors to describe what a method does not measure and where an incorrect result would matter.
The accompanying table makes the technical questions more specific. Sponsors should consider whether results depend on the tested salt or ester, an active metabolite, a prodrug, encapsulation or a carrier. A test of the active ingredient may not describe the behavior of every formulation. The table also asks for conditions under which the method fails, suitable positive and negative controls, and the effects of proprietary media, coatings or other components on reproducibility.
The amount of validation evidence should be proportionate to the significance of the data and the consequences of a wrong conclusion. TGA gives primary pharmacology evidence and safety data as examples of uses that may call for different levels of support. Its table asks about within- and between-run variability, comparator methods, limitations of the biological model and the contribution of a NAM to the overall evidence for human exposure or dose decisions.
NAM studies submitted for regulatory purposes are generally expected to follow Good Laboratory Practice requirements. TGA notes that its page links to related EMA and FDA resources for detail, but those documents have not been formally adopted by TGA.
Traceability is part of that evidence. TGA asks for model versions, relevant batch information and access dates where these affect the analysis. Its examples of regulatory contribution include first-in-human exposure, dose escalation, clinical monitoring and stopping criteria. These questions make clear why the same method can require different supporting evidence when it moves from exploratory research to a decision on human exposure.
A new FDA draft describes how in vitro potency and safety data, anchored to clinical evidence, could support variants of individualized genome-editing therapeutics within a defined product boundary.
A 1 October joint statement from medicines regulators urges validated non-animal methods across the human-medicine lifecycle, with particular emphasis on batch-release testing. Implementation remains with national and regional authorities.
